Association of tumour mutational burden (TMB) with outcomes in stage IIIA(N2) non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemotherapy and durvalumab: prospective analysis of the multicenter single-arm phase II trial SAKK16/14

被引：0

作者：

Alborelli, I ^{[1
]}

Jermann, P. M. ^{[2
]}

Leonards, K. ^{[2
]}

Manzo, M. ^{[2
]}

Keller, E. ^{[2
]}

Zippelius, A. ^{[1
,3
]}

Eboulet, E., I ^{[4
]}

Betticher, D. ^{[5
]}

Frueh, M. ^{[6
]}

Britschgi, C. ^{[7
]}

Peters, S. ^{[8
]}

Mark, M. ^{[9
]}

Ochsenbein, A. F. ^{[10
]}

Janthur, W. -D ^{[11
]}

Waibel, C. ^{[12
]}

Mach, N. ^{[13
]}

Froesch, P. ^{[14
]}

Pless, M. ^{[15
]}

Prince, Savic S. ^{[2
]}

Rothschild, S. ^{[1
]}

机构：

[1] Univ Spital Basel, Med Onkol, Basel, Switzerland

[2] Univ Spital Basel, Inst Pathol, Basel, Switzerland

[3] Univ Spital Basel, Dept Biomed Lab Tumorimmunol, Basel, Switzerland

[4] Schweizer Arbeitsgemeinschaft Klin Krebsforsch SA, Bern, Switzerland

[5] HFR Fribourg Hop Fribourgeois, Med Onkol, Fribourg, Switzerland

[6] Kantonsspital St Gallen, Onkol Hamatol, St Gallen, Switzerland

[7] Univ Spital Zurich, Med Onkol & Hamatol, Zurich, Switzerland

[8] Ctr Hosp Univ Vaudois CHUV, Med Onkol, Lausanne, Switzerland

[9] Kantonsspital Graubunden, Onkol Hamatol, Chur, Switzerland

[10] Inselspital Bern, Med Onkol, Bern, Switzerland

[11] Kantonsspital Aarau, Onkol Hamatol & Transfus Med, Aarau, Switzerland

[12] Kantonsspital Baden, Onkol Hamatol, Baden, Switzerland

[13] Hop Univ Geneve, Med Onkol, Geneva, Switzerland

[14] Ist Oncol Svizzera Italiana IOSI, Bellinzona, Switzerland

[15] Kantonsspital Winterthur, Med Onkol, Winterthur, Switzerland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ep658

引用

页码：174 / 175

页数：2

共 50 条

[41] Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trial
Chen, H.
Hu, H.
Fu, F.
ANNALS OF ONCOLOGY, 2024, 35 : S787 - S787
[42] Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: Results of CALGB Protocol 39803
Jaklitsch, Michael T.
Gu, Lin
Demmy, Todd
Harpole, David H.
D'Amico, Thomas A.
McKenna, Robert J.
Krasna, Mark J.
Kohman, Leslie J.
Swanson, Scott J.
DeCamp, Malcolm M.
Wang, Xiaofei
Barry, Susan
Sugarbaker, David J.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 146 (01): : 9 - 16
[43] Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
Tanimura, Keiko
Uchino, Junji
Kimura, Hideharu
Hiranuma, Osamu
Chihara, Yusuke
Tanzawa, Shigeru
Takumi, Chieko
Kita, Toshiyuki
Inoue, Koji
Minato, Koichi
Takemoto, Shinnosuke
Nakao, Akira
Yoshimura, Kenichi
Takayama, Koichi
ONCOLOGIST, 2023, 28 (06): : 551 - +
[44] Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Shu, Catherine A.
Gainor, Justin F.
Awad, Mark M.
Chiuzan, Codruta
Grigg, Claud M.
Pabani, Aliyah
Garofano, Robert F.
Stoopler, Mark B.
Cheng, Simon K.
White, Abby
Lanuti, Michael
D'Ovidio, Frank
Bacchetta, Matthew
Sonett, Joshua R.
Saqi, Anjali
Rizvi, Naiyer A.
LANCET ONCOLOGY, 2020, 21 (06): : 786 - 795
[45] Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)
Tsuchiya-Kawano, Yuko
Shiraishi, Yoshimasa
Tanaka, Kentaro
Tachihara, Motoko
Saito, Ryota
Okamoto, Tatsuro
Sugasaki, Nanae
Nakatomi, Keita
Kiyomi, Fumiaki
Okamoto, Isamu
EUROPEAN JOURNAL OF CANCER, 2024, 212
[46] Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial
Sun, Chao
Wang, Xu
Xu, Yinghui
Shao, Guoguang
Chen, Xi
Liu, Yunpeng
Zhang, Peng
Lin, Xingyu
Ma, Xiaobo
Qiu, Shi
He, Hua
Yang, Zhiguang
Ma, Kewei
ECLINICALMEDICINE, 2024, 68
[47] Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial
Fujimoto, Daichi
Yomota, Makiko
Sekine, Akimasa
Morita, Mitsunori
Morimoto, Takeshi
Hosomi, Yukio
Ogura, Takashi
Tomioka, Hiromi
Tomii, Keisuke
LUNG CANCER, 2019, 134 : 274 - 278
[48] Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
Sun, Chao
Liu, Yunpeng
Zhang, Peng
Wang, Xu
Xu, Yinghui
Lin, Xingyu
Ma, Xiaobo
Guo, Ye
Qiu, Shi
Shao, Guoguang
Yang, Zhiguang
Ma, Kewei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 819 - 831
[49] Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
Chao Sun
Yunpeng Liu
Peng Zhang
Xu Wang
Yinghui Xu
Xingyu Lin
Xiaobo Ma
Ye Guo
Shi Qiu
Guoguang Shao
Zhiguang Yang
Kewei Ma
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 819 - 831
[50] A phase II single-arm study of LDK378 in patients with ALK-activated (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).
Shaw, Alice Tsang
Mok, Tony
Spigel, David R.
Nishio, Makoto
Felip, Enriqueta
Tan, Daniel Shao-Weng
Garcia-Campelo, M. Rosario
Gruen, Harry J. M.
Dakhil, Shaker R.
Schaefer, Eric Scott
Farrell, Nicholas John
Blakesley, Rick E.
Weir, Alexander
Ristic, Mirta
Selvaggi, Giovanni
Scagliotti, Giorgio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →